Pharmacotherapeutic options for co-morbid depression and alcohol dependence

References

• GBD 2016 DALYs and Hale Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260–1344.
   PubMed Web of Science ®Google Scholar
• GBD Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
   PubMed Web of Science ®Google Scholar
• GBD Mortality Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden Of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.
   PubMed Web of Science ®Google Scholar
• Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–914.
   PubMed Web of Science ®Google Scholar
• Hawton K, Casanas ICC, Haw C, et al. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord. 2013;147(1–3):17–28.
   PubMed Web of Science ®Google Scholar
• Suter M, Strik W, Moggi F. Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder. J Subst Abuse Treat. 2011;41(3):225–232.
   PubMed Web of Science ®Google Scholar
• Carton L, Pignon B, Baguet A, et al. Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study. Drug Alcohol Depend. 2018;187:40–47.
   PubMed Web of Science ®Google Scholar
• Yoon G, Petrakis IL, Rosenheck RA. Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration. Am J Addict. 2015;24(5):419–426.
   PubMed Web of Science ®Google Scholar
• Andersen AM, Pietrzak RH, Kranzler HR, et al. Polygenic scores for major depressive disorder and risk of alcohol dependence. JAMA psychiatry. 2017;74(11):1153–1160.
   PubMed Web of Science ®Google Scholar
• Palmisano M, Pandey SC. Epigenetic mechanisms of alcoholism and stress-related disorders. Alcohol. 2017;60:7–18.
   PubMed Web of Science ®Google Scholar
• Hesselbrock MN, Tennen H, Hesselbrock V, et al. Assessment of depression in alcoholics: further considerations: reply to Hagan and Schauer. J Consult Clin Psychol. 1985;53(1):67–69.
   PubMed Web of Science ®Google Scholar
• Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1–22.
   PubMed Web of Science ®Google Scholar
• Sari Y. Commentary: targeting NMDA receptor and serotonin transporter for the treatment of comorbid alcohol dependence and depression. Alcohol Clin Exp Res. 2017;41(2):275–278.
   PubMed Web of Science ®Google Scholar
• Agabio R, Leggio L. Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders. Front Psychiatry. 2018;9:464.
   PubMed Web of Science ®Google Scholar
• Hillemacher T, Leggio L, Heberlein A. Investigational therapies for the pharmacological treatment of alcoholism. Expert Opin Investig Drugs. 2015;24(1):17–30.
   PubMed Web of Science ®Google Scholar
• Ding ZM, Ingraham CM, Rodd ZA, et al. Alcohol drinking increases the dopamine-stimulating effects of ethanol and reduces D2 auto-receptor and group II metabotropic glutamate receptor function within the posterior ventral tegmental area of alcohol preferring (P) rats. Neuropharmacology. 2016;109:41–48.
   PubMed Web of Science ®Google Scholar
• Pereira PA, Neves J, Vilela M, et al. Chronic alcohol consumption leads to neurochemical changes in the nucleus accumbens that are not fully reversed by withdrawal. Neurotoxicol Teratol. 2014;44:53–61.
   PubMed Web of Science ®Google Scholar
• Sari Y, Johnson VR, Weedman JM. Role of the serotonergic system in alcohol dependence: from animal models to clinics. Prog Mol Biol Transl Sci. 2011;98:401–443.
   PubMed Web of Science ®Google Scholar
• Roberto M, Varodayan FP. Synaptic targets: chronic alcohol actions. Neuropharmacology. 2017;122:85–99.
   PubMed Web of Science ®Google Scholar
• de Beaurepaire R. A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front Psychiatry. 2018;9:506.
   PubMed Web of Science ®Google Scholar
• Jacobson LH, Vlachou S, Slattery DA, et al. The gamma-aminobutyric acid B receptor in depression and reward. Biol Psychiatry. 2018;83(11):963–976.
   PubMed Web of Science ®Google Scholar
• Prisciandaro JJ, Tolliver BK, Prescot AP, et al. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017;7(7):e1163.
   PubMedGoogle Scholar
• Roberto M, Gilpin NW, Siggins GR. The central amygdala and alcohol: role of gamma-aminobutyric acid, glutamate, and neuropeptides. Cold Spring Harb Perspect Med. 2012;2(12):a012195.
   PubMed Web of Science ®Google Scholar
• Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl). 2013;229(3):539–554.
   PubMed Web of Science ®Google Scholar
• Mifflin K, Benson C, Kerr B, et al. Involvement of neuroactive steroids in pain, depression and anxiety. Mod Trends Pharmacopsychiatry. 2015;30:94–102.
   PubMedGoogle Scholar
• Marcinkiewcz CA. Serotonergic systems in the pathophysiology of ethanol dependence: relevance to clinical alcoholism. ACS Chem Neurosci. 2015;6(7):1026–1039.
   PubMed Web of Science ®Google Scholar
• Sudakin D. Naltrexone:not Just for Opioids Anymore. J Med Toxicol. 2016;12(1):71–75.
   PubMed Web of Science ®Google Scholar
• Reilly MT, Noronha A, Goldman D, et al. Genetic studies of alcohol dependence in the context of the addiction cycle. Neuropharmacology. 2017;122:3–21.
   PubMed Web of Science ®Google Scholar
• Leclercq S, de Timary P, Delzenne NM, et al. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017;7(2):e1048.
   PubMedGoogle Scholar
• Gonzalez-Reimers E, Santolaria-Fernandez F, Martin-Gonzalez MC, et al. Alcoholism: a systemic proinflammatory condition. World J Gastroenterol. 2014;20(40):14660–14671.
   PubMed Web of Science ®Google Scholar
• Szabo G, Lippai D. Converging actions of alcohol on liver and brain immune signaling. Int Rev Neurobiol. 2014;118:359–380.
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Diamantouros A, Schaffer A, et al. Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs. 2006;66(9):1229–1237.
   PubMed Web of Science ®Google Scholar
• Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry. 2005;13(6):491–500.
   PubMed Web of Science ®Google Scholar
• Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57(12):572–575.
   PubMed Web of Science ®Google Scholar
• Ciraulo DA, Jaffe JH. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol. 1981;1(3):146–150.
   PubMed Web of Science ®Google Scholar
• Jaffe JH, Ciraulo DA, Nies A, et al. Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawal. Clin Pharmacol Ther. 1983;34(5):623–630.
   PubMed Web of Science ®Google Scholar
• Shaw JA, Donley P, Morgan DW, et al. Treatment of depression in alcoholics. Am J Psychiatry. 1975;132(6):641–644.
   PubMed Web of Science ®Google Scholar
• Ostacher MJ. Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment. Psychiatr Clin North Am. 2007;30(1):69–76.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23–30.
   PubMed Web of Science ®Google Scholar
• Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56(10):785–792.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
   PubMed Web of Science ®Google Scholar
• Goyer PF, Brown GL, Minichiello MD, et al. Mood-altering effects of disulfiram in alcoholics. J Stud Alcohol. 1984;45(3):209–213.
   PubMedGoogle Scholar
• Petrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27(2):160–165.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Bhatt S, Bohan J, et al. Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study. Am J Drug Alcohol Abuse. 2016;42(5):490–499.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Chapter 3—Disulfiram. In: Incorporating alcohol pharmacotherapies into medical practice. Rockville (MD): Substance Abuse and Mental Health Services Administration (US);2009.
   Google Scholar
• Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016;26(12):1950–1959.
   PubMed Web of Science ®Google Scholar
• Morley KC, Baillie A, Leung S, et al. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654–660.
   PubMed Web of Science ®Google Scholar
• Morley KC, Lagopoulos J, Logge W, et al. Neurometabolite levels in alcohol use disorder patients during baclofen treatment and prediction of relapse to heavy drinking. Front Psychiatry. 2018;9:412.
   PubMed Web of Science ®Google Scholar
• Pierce M, Sutterland A, Beraha EM, et al. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795–806.
   PubMed Web of Science ®Google Scholar
• Garbutt JC. Use of baclofen for alcohol use disorders in the United States. Front Psychiatry. 2018;9:448.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Schwandt ML, Lee MR, et al. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017;7(4):e1108.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Burakov AM, Ivanov VB, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993;33(2):157–163.
   PubMed Web of Science ®Google Scholar
• Salloum IM, Cornelius JR, Thase ME, et al. Naltrexone utility in depressed alcoholics. Psychopharmacol Bull. 1998;34(1):111–115.
   PubMedGoogle Scholar
• Kiefer F, Helwig H, Tarnaske T, et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res. 2005;11(2):83–91.
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451–1462.
   PubMed Web of Science ®Google Scholar
• Reus VI, Fochtmann LJ, Bukstein O, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90.
   Google Scholar
• Mann K, Torup L, Sorensen P, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016;26(12):1941–1949.
   PubMed Web of Science ®Google Scholar
• Montesinos J, Gil A, Guerri C. Nalmefene prevents alcohol-induced neuroinflammation and alcohol drinking preference in adolescent female mice: role of TLR4. Alcohol Clin Exp Res. 2017;41(7):1257–1270.
   PubMed Web of Science ®Google Scholar
• Cheng T, Wallace DM, Ponteri B, et al. Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects. Neuropsychiatr Dis Treat. 2018;14:1351–1361.
   PubMed Web of Science ®Google Scholar
• Overall JE, Brown D, Williams JD, et al. Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatry. 1973;29(2):218–225.
   PubMedGoogle Scholar
• Carlsson C, Fasth BG. A comparison of the effects of propranolol and diazepam in alcoholics. Br J Addict Alcohol Other Drugs. 1976;71(4):321–326.
   PubMedGoogle Scholar
• Lovinger DM, Alvarez VA. Alcohol and basal ganglia circuitry: animal models. Neuropharmacology. 2017;122:46–55.
   PubMed Web of Science ®Google Scholar
• Maler JM, Esselmann H, Wiltfang J, et al. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res. 2005;1052(2):156–162.
   PubMed Web of Science ®Google Scholar
• Muhonen LH, Lahti J, Sinclair D, et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder–predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy. 2008;3:20.
   PubMed Web of Science ®Google Scholar
• Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat. 2006;2(4):475–488.
   PubMedGoogle Scholar
• Martinotti G, Di Nicola M, De Vita O, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):709–715.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54(8):700–705.
   PubMed Web of Science ®Google Scholar
• Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998;44(7):633–637.
   PubMed Web of Science ®Google Scholar
• Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol. 2003;38(6):619–625.
   PubMed Web of Science ®Google Scholar
• Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23(6):553–562.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Mueller T, Cornelius J, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006;26(1):13–20.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668–675.
   PubMed Web of Science ®Google Scholar
• Balaratnasingam S, Janca A. Combining sertraline and naltrexone in the treatment of adults with comorbid depression and alcohol dependence. Curr Psychiatry Rep. 2011;13(4):245–247.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Yerish S, Kiselev A. P.6.a.002 Clinical trial of escitalopram for alcoholism comorbid with affective disorders. Eur Neuropsychopharmacol. 2010;20:S571.
   Web of Science ®Google Scholar
• Witte J, Bentley K, Evins AE, et al. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012;32(6):787–796.
   PubMed Web of Science ®Google Scholar
• Han DH, Kim SM, Choi JE, et al. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol. 2013;27(3):282–291.
   PubMed Web of Science ®Google Scholar
• Adamson SJ, Sellman JD, Foulds JA, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2015;35(2):143–149.
   PubMed Web of Science ®Google Scholar
• Cocchi R. Paroxetine vs amitryptiline in depressed alcoholics. Eur Neuropsychopharmacol. 1997;1002(7):S254.
   Google Scholar
• Brown ES, Bobadilla L, Nejtek VA, et al. Open-label nefazodone in patients with a major depressive episode and alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):681–685.
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Pages KP, Russo JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20(2):129–136.
   PubMed Web of Science ®Google Scholar
• Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcohol Clin Exp Res. 2004;28(3):433–440.
   PubMed Web of Science ®Google Scholar
• Monti JM, Alterwain P, Estevez F, et al. The effects of ritanserin on mood and sleep in abstinent alcoholic patients. Sleep. 1993;16(7):647–654.
   PubMed Web of Science ®Google Scholar
• Asheychik R, Jackson T, Baker H, et al. The efficacy of L-tryptophan in the reduction of sleep disturbance and depressive state in alcoholic patients. J Stud Alcohol. 1989;50(6):525–532.
   PubMedGoogle Scholar
• Loo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology. 1988;19(2):79–85.
   PubMed Web of Science ®Google Scholar
• Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008;23(4):313–319.
   PubMed Web of Science ®Google Scholar
• Butterworth AT, Watts RD. Treatment of hospitalized alcoholics with doxepin and diazepam. A controlled study. Q J Stud Alcohol. 1971;32(1):78–81.
   PubMedGoogle Scholar
• Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993;150(6):963–965.
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53(3):232–240.
   PubMed Web of Science ®Google Scholar
• Vukovic O, Maric NP, Britvic D, et al. Efficacy, tolerability and safety of tianeptine in special populations of depressive patients. Psychiatr Danub. 2009;21(2):194–198.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275(10):761–767.
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Pae CU, Kim DJ, et al. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1196–1201.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Douaihy AB, Clark DB, et al. Mirtazapine in comorbid major depression and alcohol dependence: an open-label trial. J Dual Diagn. 2012;8(3):200–204.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Chung T, Douaihy AB, et al. Mirtazapine in comorbid major depression and an alcohol use disorder: a double-blind placebo-controlled pilot trial. Psychiatry Res. 2016;242:326–330.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Mauri MC, Girardi T, et al. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10(5):293–298.
   PubMedGoogle Scholar
• Malhi GS. Lithium: a global perspective. Pharmacopsychiatry. 2018;51(05):220–221.
   PubMedGoogle Scholar
• Kline NS, Wren JC, Cooper TB, et al. Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci. 1974;268(1):15–22.
   PubMed Web of Science ®Google Scholar
• Merry J, Reynolds CM, Bailey J, et al. Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet. 1976;1(7984):481–482.
   PubMedGoogle Scholar
• Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262(12):1646–1652.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23(5):417–424.
   PubMed Web of Science ®Google Scholar
• Svendsen CN, Froimowitz M, Hrbek C, et al. Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. Neuropharmacology. 1988;27(11):1117–1124.
   PubMed Web of Science ®Google Scholar
• Hague WH, Wilson LG, Dudley DL, et al. Post-detoxification drug treatment of anxiety and depression in alcohol addicts. J Nerv Ment Dis. 1976;162(5):354–359.
   PubMed Web of Science ®Google Scholar
• Manzardo AM, Pendleton T, Poje A, et al. Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity. Drug Alcohol Depend. 2015;152:257–263.
   PubMed Web of Science ®Google Scholar
• Tapias V, Jainuddin S, Ahuja M, et al. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet. 2018;27(16):2874–2892.
   PubMed Web of Science ®Google Scholar
• Shaw GK, Majumdar SK, Waller S, et al. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry. 1987;150:164–168.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. Addict Behav. 2000;25(2):307–310.
   PubMed Web of Science ®Google Scholar
• Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018;4:Cd008581.
   PubMedGoogle Scholar
• Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA. 2004;291(15):1887–1896.
   PubMed Web of Science ®Google Scholar
• Aharonovich E, Liu X, Nunes E, et al. Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry. 2002;159(9):1600–1602.
   PubMed Web of Science ®Google Scholar
• Greenfield SF, Weiss RD, Muenz LR, et al. The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry. 1998;55(3):259–265.
   PubMed Web of Science ®Google Scholar
• Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002;59(4):375–380.
   PubMed Web of Science ®Google Scholar
• Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des. 2010;16(19):2126–2135.
   PubMed Web of Science ®Google Scholar
• Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;75(Suppl 17):79–88.
   PubMedGoogle Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619–626.
   PubMed Web of Science ®Google Scholar
• McAndrew A, Lawn W, Stevens T, et al. A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials. 2017;18(1):159.
   PubMedGoogle Scholar
• Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21(2):143–153.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Tennen H, et al. 5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity. Addict Biol. 2013;18(6):1024–1031.
   PubMed Web of Science ®Google Scholar